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Abstract
Background: Bone morphogenetic protein (BMP)-2 and growth and differentiation factor (GDF)-5 are two related
transforming growth factor (TGF)-β family members with important functions in embryonic development and tissue
homeostasis. BMP-2 is best known for its osteoinductive properties whereas GDF-5—as evident from its alternative
name, cartilage derived morphogenetic protein 1—plays an important role in the formation of cartilage. In spite of
these differences both factors signal by binding to the same subset of BMP receptors, raising the question how
these different functionalities are generated. The largest difference in receptor binding is observed in the interaction
with the type I receptor BMPR-IA. GDF-5, in contrast to BMP-2, shows preferential binding to the isoform BMPR-IB,
which is abrogated by a single amino acid (A57R) substitution. The resulting variant, GDF-5 R57A, represents a “BMP-2
mimic” with respect to BMP receptor binding. In this study we thus wanted to analyze whether the two growth factors
can induce distinct signals via an identically composed receptor.
Results: Unexpectedly and dependent on the cellular context, GDF-5 R57A showed clear differences in its activity
compared to BMP-2. In ATDC-5 cells, both ligands induced alkaline phosphatase (ALP) expression with similar potency.
But in C2C12 cells, the BMP-2 mimic GDF-5 R57A (and also wild-type GDF-5) clearly antagonized BMP-2-mediated ALP
expression, despite signaling in both cell lines occurring solely via BMPR-IA. The BMP-2- antagonizing properties of
GDF-5 and GDF-5 R57A could also be observed in vivo when implanting BMP-2 and either one of the two GDF-5
ligands simultaneously at heterotopic sites.
Conclusions: Although comparison of the crystal structures of the GDF-5 R57A:BMPR-IAEC- and BMP-2:BMPR-IAEC
complex revealed small ligand-specific differences, these cannot account for the different signaling characteristics
because the complexes seem identical in both differently reacting cell lines. We thus predict an additional component,
most likely a not yet identified GDF-5-specific co-receptor, which alters the output of the signaling complexes. Hence
the presence or absence of this component then switches GDF-5′s signaling capabilities to act either similar to BMP-2
or as a BMP-2 antagonist. These findings might shed new light on the role of GDF-5, e.g., in cartilage maintenance
and/or limb development in that it might act as an inhibitor of signaling events initiated by other BMPs.
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Background
Functional synovial joints are essential to ensure proper
biomechanical function of the skeleton and are formed
from a mesenchymal interzone emerging at each pro-
spective joint site [1, 2]. Despite the understanding that
this interzone region is essential for joint formation, the
specific developmental roles, fate, and mechanisms of
action of the participating cells remain poorly under-
stood [3]. Molecular and genetic studies have revealed
that interzone cells express a number of genes from the
Wnt and transforming growth factor (TGF)-β pathway
including wnt-9a, wnt-4, noggin, and gdf-5 [4–7]. Most
importantly, proper joint formation requires the inter-
vention of gene products with both chondrogenic and
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anti-chondrogenic activities. Aside from growth and dif-
ferentiation factor (GDF)-5, several other members of
the bone morphogenetic protein (BMP) family are also
expressed in stripes at sites of joint formation, including
those encoded by the genes gdf-6, bmp-2, and bmp-4
[8–11]. Several mutations in either gdf-5 or the closely
related gdf-6 gene impair joint formation at specific loca-
tions, thereby strongly indicating that these molecules are
absolutely essential for the joint formation process [6, 9].
GDF-5, like BMP-2 and BMP-4, binds to and oligo-
merizes two types of serine-/threonine kinase transmem-
brane receptors, termed TGF-β superfamily type I and
type II receptors [12, 13]. Of the seven different known
type I receptors, BMPR-IA and BMPR-IB have been im-
plicated in skeletal patterning. Mice with null mutations
in the bmpr-1b gene are viable, but show defects in bone
and joint formation closely resembling those seen in
mice lacking GDF-5 [10, 14]. In contrast, mice with null
mutations in bmpr-1a die early during embryogenesis
[15]. However, a conditional knockout of bmpr-1a under
the control of a GDF5-Cre driver allows the bypassing of
embryonic lethality and yields viable mice with seem-
ingly normal joints. But the progressive loss of articular
cartilage within the joints of those conditional knockout
mice strongly resembles the disease mechanism of
osteoarthritis [16]. This observation clearly highlights
the importance of BMPR-IA in cartilage homeostasis
and repair.
In vitro interaction analysis demonstrated that GDF-5
binds the extracellular domains of the individual type II
receptors ActR-II, ActR-IIB, and BMPR-II as well as the
type I receptor BMPR-IB, with similar binding affinities
as found for BMP-2 [17]. The most striking difference
has been detected in the binding properties of BMP-2
and GDF-5 to the type I receptor BMPR-IA. Whereas
BMP-2 binds to both type I receptors—BMPR-IA and
BMPR-IB—with similar affinities, GDF-5 exhibits a 12-
fold higher affinity for BMPR-IB than for BMPR-IA. This
type I receptor specificity of GDF-5 is due to a single
amino acid, Arg57, which is located in the pre-helix loop
of the ligand [18, 19]. Mutation of Arg57 in GDF-5 to
alanine abrogates type I receptor specificity completely,
whereas the mutation of Arg57 to leucine leads to en-
hanced binding to BMPR-IA and attenuated type I re-
ceptor specificity [18, 19]. The latter mutation is found
in patients with proximal symphalangism (SYM1), a rare
disease characterized by a joint fusion of the middle and
distal phalanges of the fourth digit. Its phenotype is very
similar to that caused by mutations in Noggin, a modu-
lator protein counteracting GDF-5 activity [18], and ra-
ther different to other mutations in GDF-5 found in
patients with brachydactyly and Du Pan syndrome (also
known as fibula aplasia complex brachydactyly). Muta-
tions leading to the latter two phenotypes usually disrupt
GDF-5 receptor binding and/or activity [18, 20] and are
characterized by hypoplasia or aplasia of individual middle
phalanges of different digits. Because only the binding af-
finity for BMPR-IA is increased in both GDF-5 variants
(R57A and R57L), it can be assumed that the resulting
SYM1 phenotype is due to a shift in receptor specificity.
That GDF-5 can indeed signal via BMPR-IA is evident
from the observation that BMP-2 and the GDF-5 variant
R57L induce expression of alkaline phosphatase (ALP) in
the chondrocyte cell line ATDC-5 with similar efficiency
[18], a cell line lacking BMPR-IB [21]. Consistently, wild-
type GDF-5 induces ALP expression in these cells but,
compared to GDF-5 R57L and GDF-5 R57A, a 10-fold
higher concentration is required for a half maximal re-
sponse (EC50) [18, 19], which nicely correlates with the
different binding affinities of these different GDF-5 pro-
teins for BMPR-IA. Surprisingly and in contrast to the
above observation, in C2C12 cells, a promyoblast cell line
also carrying the BMPR receptor BMPR-IA, ALP expres-
sion can be induced by BMP-2, but not by GDF-5 [21].
Furthermore, the GDF-5 variant R57L, despite being a
BMP-2 mimic with a similar BMPR-IA binding profile as
BMP-2, stimulates only weak ALP expression [18], indi-
cating that the ALP expression by GDF-5 is cell-line
specific.
To further investigate this discrepancy in signaling
outcome, we examined the biological activities of BMP-
2, GDF-5, and GDF-5 R57A in vitro using cell-based as-
says. We compared the results with data from in vivo
models, in which ligand-doped carriers were implanted
into rat hind limbs (heterotopic model) or calvaria
(orthotopic model). Structural studies were performed
by crystallizing the binary complex of GDF-5 R57A
bound to BMPR-IA and determining its structure at
high resolution. On the basis of this structure the mo-
lecular mechanism by which GDF-5 possibly discrimi-
nates between the two type I receptors BMPR-IA and
BMPR-IB could be analyzed. The biological activities of
GDF-5 analyzed in cell-based assays as well as in vivo
could then be correlated to aspects of ligand receptor
assembly.
Results
Structure of the binary complex of GDF-5 R57A bound
to BMPR-IA
Similar to other BMP-BMP type I receptor complexes
[22–24], BMPR-IA is bound to the so-called wrist epi-
tope of GDF-5 formed by the finger region of one GDF-
5 monomer and the helix and pre-helix loop of the
second GDF-5 monomer subunit [PDB:3QB4] [24]. Al-
though a full complex—one GDF-5 R57A dimer and two
BMPR-IAEC molecules (Fig. 1a, b)—was observed in the
asymmetric unit of the crystal, the backbone of the lig-
and–receptor complex was highly symmetrical, as shown
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from the superposition of the two GDF-5 monomers as
well as the BMPR-IA ectodomains (Additional file 1:
Figure S1). Analysis of the two binding interfaces formed
by the homodimeric GDF-5 and the two BMPR-IA mol-
ecules yielded a total of 18 intermolecular hydrogen
bonds (H-bonds), suggesting that polar bonds play a role
in GDF-5 type I receptor recognition and binding
(Table 1). However, because the 18 H-bonds were
formed from 12 pairs of polar groups, the H-bond net-
work was not identical in the two otherwise identical in-
terfaces (Table 1). In interface 1 of the GDF-5 R57A:
BMPR-IAEC complex, 11 H-bonds were found between
the ligand and the receptor, whereas in interface 2, only
seven H-bonds were observed (Table 1). A comparison
showed that six H-bonds were identically formed in both
interfaces with highly similar length and angles, there-
fore potentially representing the physiologically import-
ant core of the polar interactions.
GDF-5 undergoes an induced fit mechanism upon
binding to type I receptors
For GDF-5, superposition of the free [PDB:1WAQ] [19]
and bound structures yielded an root mean square
(r.m.s.) deviation of 1.7 Å for all Cα-atom positions, but
significant differences were mainly observed for the tips
of fingers 1 and 2 (Fig. 2a, b). Upon binding of GDF-5
R57A to BMPR-IAEC, the backbone atoms of residues
Phe97 to Val104 (finger 2) and Lys29 to Ile38 (ω-loop in
finger 1) of GDF-5 R57A moved up by 5.5 Å towards
BMPR-IA, although residues in the very tips of finger 2
shared no contact with BMPR-IA. With regards side
chain rearrangements, the largest changes were observed
for the two tryptophans in the wrist epitope of GDF-5
R57A (Fig. 2c); Trp33 moved downwards by about 4 Å
and Trp36 rotated from a highly solvent-exposed con-
formation into a position located above Trp33 thereby
moving by almost 10 Å. Residues in the α-helix showed
no conformational changes upon complex formation
and residues in the pre-helix loop of GDF-5 R57A, the
latter of which is considered to be rather flexible in
BMP-2 [22], shifted by 2.2 Å (residues Phe54 to Pro55)
at the N-terminal start of the pre-helix loop. A
Fig. 1 Architecture of the binary GDF-5 R57A:BMPR-IAEC complex. Ribbon plot of the binary complex of GDF-5 R57A (monomer subunits colored
in blue and cyan) bound to the extracellular domain of BMPR-IA (green). a View from the side, the side facing the putative cell surface is indicated.
b As in (a) but viewed from the top showing the two-fold symmetry of the homodimeric GDF-5 as well as of the ligand-receptor complex.
Disulfide bonds forming the two cystin-knot motifs in the GDF-5 monomer subunits and the intermolecular disulfide bond are shown as yellow
sticks. The location of the knuckle epitope important for BMP type II receptor binding is indicated
Table 1 Geometry of H-bonds in the GDF-5 R57A:BMPR-IAEC
interface
GDF-5 R57A BMPR-IAEC Distance Å Angle N–O–C
a H-bondb
R18 (NE) G42 (O) 3.19 (−) 162 (−) SC-MC
W33 (NE1) D89 (O) 2.94 (−) 133 (−) SC-MC
L56 (N) Q86 (OE1) 2.88 (2.81) 140 (143) MC-SC
L56 (O) Q86 (NE2) 3.12 (3.19) 137 (140) MC-SC
S58 (N) C77 (O) 2.74 (2.86) 129 (130) MC-MC
S58 (OG) T55 (OG1) 2.93 (2.54) 99 (121) SC-SC
E61 (OE2) K79 (NZ) 3.26 (−) 125 (−) SC-SC
M31 (O) S90 (OG) 2.55 (−) 136 (−) MC-SC
S74 (O) Q94 (N) 2.83 (3.03) 149 (142) MC-MC
S74 (OG) R97 (NH2) - (2.87) - (132) SC-SC
K107 (NZ) D84 (OD2) 3.01 (−) 117 (−) SC-SC
Y109 (OH) D84 (OD2) 2.61 (2.62) 132 (139) SC-SC
Mean value 2.94 (2.84) 131/139 (135/136)
S.D. 0.21 (0.22) 10 (13)
A total of 18 intermolecular H-bonds were found in the two interfaces between
the GDF-5 dimer and the two BMPR-IA receptors. These non-covalent interactions
were formed between 12 atom pairs resulting in an uneven distribution of the
18 H-bonds. The numbers in parentheses are the distances between donor and
acceptor atoms and N–O–C angles in the second interface, related by
non-crystallographic symmetry
aN, O, C are the donor-acceptor atoms; from general statistics20 this angle is
149 ° ±15 ° for MC–MC hydrogen bonds and 129 ° ±18 ° for SC–MC and
SC–SC H-bonds
bMC (main chain) and SC (side chain) donor/acceptor atoms
Klammert et al. BMC Biology  (2015) 13:77 Page 3 of 18
Fig. 2 Conformational rearrangement of GDF-5 upon complex formation. a Structural alignment of unbound (green) and GDF-5 R57A (blue/cyan)
bound to BMPR-IA showing an induced fit rearrangement of the tips of finger 1 and 2 upon type I receptor binding. b As in (a) but viewed from
the top. Upon binding to BMPR-IA, finger 1 and 2 of GDF-5 move towards the BMP type I receptor surface (shown as transparent van der Waals
surface representation). c Stereoview of the conformational change of GDF-5 upon type I receptor binding. The side chain of Trp33 and Trp36
show the largest rearrangement, moving up to 10 Å. d Structural alignment of GDF-5 (wild-type) bound to BMPR-IB (magenta/rose) and GDF-5
R57A (blue/cyan) bound to BMPR-IA showing that the bound conformation of GDF-5 is almost identical irrespective of the type I receptor bound.
e Different spatial requirements due to amino acid differences between BMPR-IA (black, only residues Glu81 to Gln94 are shown) and BMPR-IB
(magenta ribbon plot) result in a small but significant bending of the α-helix 1 of GDF-5 (GDF-5 bound to BMPR-IA shown in cyan, GDF-5 bound
to BMPR-IB colored in rose)
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comparison of the complexes of GDF-5 R57A bound to
BMPR-IAEC and wild-type GDF-5 bound to BMPR-IBEC
[PDB:3EVS] [24] revealed that the structures of “bound”
GDF-5 were highly similar irrespective of what type I re-
ceptor was bound (Fig. 2d). The observation indicates
that the induced fit of GDF-5 upon complex formation,
e.g., the “closing” of the two finger tips, possibly follows
a route independent of the exact nature of the type I re-
ceptor. Thus GDF-5 seems to “snap” into an imprinted
bound conformation upon binding to a type I receptor.
The only small differences in the backbone conforma-
tions of GDF-5 and GDF-5 R57A bound to either
BMPR-IAEC or BMPR-IBEC were observed for residues
Ser74 to Thr80, covering the last turn of the α-helix and
the loop in front of β-strand 5 of finger 2. Owing to dif-
ferences in the structures of the contacting loops of
BMPR-IA and BMPR-IB, these residues shifted by 1.3–
2.6 Å; in GDF-5 in complex with BMPR-IBEC, this re-
gion was pushed away from the GDF-5 surface to pro-
vide more space for several bulkier amino acid residues
in BMPR-IB (e.g., Thr71 BMPR-IB versus Ser90 BMPR-
IA; Ile73 BMPR-IB versus Ala93 BMPR-IA) (Fig. 2e).
The receptor BMPR-IA adopts a similar conformation
when bound to different BMP ligands
For BMPR-IA, structure determination by nuclear mag-
netic resonance and comparison with its structure bound
to BMP-2 revealed a large induced fit upon complex for-
mation with BMP-2 [25]. The β4β5-loop of BMPR-IA,
which is the central element of the BMP receptor–ligand
interaction, was disordered in the “free” BMPR-IA,
whereas the conformation of this loop was constrained
when bound to BMP-2 and contained a short 1.5-turn
helix (Gly82–Asp89). In complex with GDF-5 R57A, the
α-helix of BMPR-IA formed similarly as seen in the com-
plex with BMP-2, consistent with the observation in the
study of Klages et al. [25] that small changes in the envir-
onment result in spontaneous α-helix formation (Fig. 3a).
Also, a similar intermolecular H-bond network emanated
from residues located within the α-helix of BMPR-IAEC
involving the backbone of Leu56 of GDF-5 R57A to the
carboxamide group of BMPR-IA Gln86 (Table 1). The
aromatic side chain of Phe85 of BMPR-IA made similar
hydrophobic “knob into hole” contacts with GDF-5 R57A
as seen in BMP-2:BMPR-IAEC. Importantly, because the
complex of BMPR-IAEC bound to GDF-5 R57A repre-
sented the first structure of BMPR-IAEC bound to a BMP
ligand other than BMP-2, we were able to compare the in-
fluence of different ligands on the structure of BMPR-IA
and analyze whether the promiscuous binding of BMP re-
ceptors to various ligands is due to structural plasticity in
their binding site.
Superimposing BMPR-IA bound to GDF-5 R57A or
BMP-2 showed an almost identical conformation for
BMPR-IAEC as evident from an r.m.s. deviation of only
0.7 Å for the Cα atoms of residues Pro34 to Pro117
(Fig. 3b). None of the Cα-atom positions in the BMPR-IA
molecules bound to either GDF-5 or BMP-2 differed by
more than 1 Å. Even when all heavy atoms were consid-
ered, significant differences were only observed for side
chains located at the solvent accessible surface of BMPR-
IA outside the binding site (r.m.s. deviation 1.5 Å for
Pro34 to Pro117). Because BMPR-IAEC seemed to adopt
the same structure irrespective of whether it was bound to
GDF-5 R57A or BMP-2, alterations in the receptor struc-
ture required for the adaptation to different ligand
surfaces might be minimized by small concomitant adap-
tations in the ligand and the receptor.
Orientation of the BMPR-IA ectodomain differs among
BMP ligand-receptor complexes
Although the structures of the ligands as well as of
BMPR-IA were almost identical in the different com-
plexes with varying binding partners, superposition of
the complexes of GDF-5 R57A:BMPR-IA and BMP-
2:BMPR-IA revealed that the orientation/position of the
receptor ectodomain in its binding site differed between
these complexes (Fig. 3c). This became evident when the
Cα-atoms of both ligand molecules were superimposed,
showing that the butterfly-like architecture of the BMP-
2 and GDF-5 backbone overlapped almost perfectly.
Distances between the Cα-atoms of Glu81 of both
BMPR-IA molecules in either GDF-5 R57A:BMPR-IA or
BMPR-2:BMPR-IA, which was located at the membrane-
distal part of the receptor epitope, then showed dif-
ferences of 2.3 Å with the shorter distance present in
GDF-5 R57A:BMPR-IA. Similarly, measuring the dis-
tance between the Cα-atoms of Thr72, which was lo-
cated at the membrane-proximal part of BMPR-IA,
revealed a difference of 2.6 Å when both complexes were
compared. The Cα-atom of Gln86 could be considered
as a center of rotation for the BMPR-IA molecule. Be-
cause the above-mentioned distances reflect distances
above and below the center of rotation, the differences
observed between both complexes indicated that the
BMPR-IA moieties were exhibiting a different tilt angle
with respect to each other as well as with respect to the
ligand (Fig. 3c, d). Indeed, when defining a line through
the Cα-atoms of Thr72 (β-strand 4) and Glu81 (C-terminal
end of β-strand 4) at the edges (or a plane by additionally
using Glu64 in β-strand 3) and calculating the angles be-
tween the lines/planes of the two BMPR-IA molecules in
both BMP receptor complexes, the tilting of the two re-
ceptor moieties differed by about 10 °. From this compari-
son we determined that the membrane-distal part of the
BMPR-IA molecules swiveled towards the N-terminal end
of the GDF-5 R57A α-helix and further into the concave
wrist epitope, whereas the membrane-proximal half of the
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receptor swung out of the binding site compared to the
receptor orientation observed for the BMP-2:BMPR-IA
complex. It seems that this different receptor orientation/
tilting depends on the nature of the ligand, because redo-
ing the analysis with GDF-5 R57A:BMPR-IA and GDF-
5:BMPR-IB yielded a similar receptor tilting with less than
1 ° difference. This observation might explain the lack of
structural plasticity seen in the structures of BMPR-IAEC
bound to GDF-5 or BMP-2. Instead of the BMPR-IA re-
ceptor ectodomain adopting different conformations to
adapt to variations in the surface geometries of GDF-5
and BMP-2, the altered tilting of the receptor accommo-
dates differences in the partner’s binding site geometry.
Specific recognition of the type I receptors BMPR-IA and
BMPR-IB due to a spring-loaded latch in GDF-5
On a molecular level, discrimination of GDF-5 between
the two type I receptors is likely due to different
conformations of the β1β2-loop in the receptors, thereby
generating or releasing steric hindrance. In the crystal
structure of GDF-5 bound to BMPR-IBEC, the β1β2-loop
is in an open conformation, providing enough space for
the bulky side chain of Arg57 of GDF-5 [24] (Fig. 4a, b;
Additional file 2: Figure S2). Modeling of the complex of
GDF-5 bound to BMPR-IAEC using the structure of
BMP-2:BMPR-IAEC [PDB:1REW] [22] suggested that the
loop of BMPR-IA might adopt a “closed” conformation,
but the differences observed in the receptor tilting
between the complexes GDF-5:BMPR-IBEC and BMP-
2:BMPR-IAEC did not allow for a definite conclusion.
The structure of the GDF-5 variant R57A bound to
BMPR-IAEC, however, proved this theory to be correct.
The β1β2-loop conformation of the receptor BMPR-
IAEC was identical in both complexes, with BMPR-IA
bound to either GDF-5 R57A or BMP-2 (Fig. 4c). Thus
with the β1β2-loop of BMPR-IAEC adopting the same
Fig. 3 Ligand-dependent reorientation of the receptor ectodomain. a Comparison of the structure of unbound BMPR-IA, the structure ensemble
comprising 21 structures [PDB:2K3G] is shown as a red Cα-trace, and BMPR-IA bound to GDF-5 R57A (blue). b Structure alignment of BMPR-IA bound to
GDF-5 R57A (blue) and bound to BMP-2 (green). The Cα-traces of both BMPR-IA structures overlap almost perfectly; minor conformational differences of
the backbone are only observed for the β3β4-loop and the C-terminus. c Superposition of the complexes GDF-5 R57A:BMPR-IA and BMP-2:BMPR-IA
reveals that the BMPR-IA ectodomains adopt slightly different orientations as illustrated by lines running through the Cα-atoms of Glu81 and Thr72
(magenta line BMPR-IA of the complex GDF-5 R57A:BMPR-IA; green line BMPR-IA of the BMP-2:BMPR-IA complex, the Cα position of either Thr72 or
Glu81 is indicated by arrows). d Magnification of the two BMPR-IA molecules bound to GDF-5 R57A or bound to BMP-2 showing the different tilt angle
of the BMPR-IA moieties in both ligand–receptor complexes. The Cα-atom positions of residues Thr72 and Glu81 in the BMPR-IA molecules are
indicated by black circles (BMPR-IA from the complex when bound to BMP-2) and gray circles (BMPR-IA from the complex when bound to GDF-5 R57A)
showing the differing orientation of both BMPR-IA molecules in the complex. Superpositioning of both BMPR-IA moieties shows that the orientational
difference is not due to ligand-induced different conformations within the BMPR-IA molecules
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closed conformation as observed in the complex BMP-
2:BMPR-IAEC, residue His43 in the β1β2-loop of BMPR-
IA would clash with Arg57 of GDF-5 (Fig. 4a, b). To re-
lease this steric hindrance either the β1β2-loop has to
change its backbone conformation or the side chain of
Arg57 of GDF-5 has to reorient. Because Arg57 is tightly
packed by surrounding residues from GDF-5 as well as
residues from the receptor BMPR-IA, it is more likely
that the β1β2-loop of BMPR-IA reorients to create space
for Arg57.
GDF-5 inhibits BMP-2 induced ALP expression in
C2C12 cells
BMP-2 can induce ALP expression in ATDC-5 and in
C2C12 cells with similar efficacy [18, 19, 26]. In contrast,
wild-type GDF-5 as well as the variants R57L [18] and
R57A (Fig. 5a; Additional file 3: Figure S3) exhibited sig-
nificant induction of ALP only in ATDC5 cells. For the
two GDF-5 variants this result was rather unexpected.
Their binding affinities to all type I and type II receptors
are highly comparable if not identical to BMP-2, and it
was thus expected that, owing to their BMP-2-mimicking
receptor binding properties, BMP-2-like activities would
be observed [17]. To directly compare the biological activ-
ities of the ligands, ALP assays using C2C12 cells were
performed (Fig. 5a). To test whether GDF-5 or GDF-5
R57A can compete for BMP-2-mediated ALP induction,
and thus indeed utilize the same BMP receptors as BMP-
2, the cells were treated simultaneously with 20 nM of
BMP-2 and increasing concentrations of GDF-5 or the
variant R57A (Fig. 5b).
The direct comparison of the three ligands revealed
clear differences in their ALP-inducing potential. Addition
of up to 250 nM of GDF-5 did not increase ALP levels in
these cells, and GDF-5 R57A showed only slightly in-
creased ALP activities even at high concentrations despite
being considered a BMP-2 mimic (Fig. 5a). Instead, a
competition assay revealed a dose-dependent reduction of
BMP-2-induced ALP activity upon simultaneous addition
of either one of the respective GDF-5 ligands (Fig. 5b).
The inhibitory effect of the R57A variant (IC50 5 nM) was
~14-fold stronger compared to that of wild-type GDF-5
(IC50 70 nM), which directly correlates with the increased
affinity of GDF-5 R57A for BMPR-IA. It is important to
note that the IC50 values determined here were basically
identical to the EC50 values observed for the GDF-5 li-
gands in ALP assays using ATDC-5 cells (Additional file 3:
Figure S3). Accordingly, the inhibitory function seems
most likely to result from competition for a common
receptor-binding site present in both ATDC-5 and C2C12
cells. But, based on the cellular context, both GDF-5 vari-
ants act either as an agonist or an antagonist.
Expression profiles of BMP receptors and co-receptors are
highly similar in ATDC-5 and C2C12 cells
To investigate whether these opposing GDF-5 activities
result from differences in the expression profile of BMP
receptors or known co-receptors, quantitative reverse
transcription polymerase chain reaction (qRT-PCR) ex-
periments were performed using mRNA libraries derived
from non-stimulated ATDC-5 and C2C12 cells (Fig. 5c, d;
for primer sequences and statistics see Additional file 4:
Table S1). The expression levels for each BMP receptor
type were highly similar in ATDC-5 and C2C12 cells (dif-
ference below 2-fold), except for ActR-IIB. In the case of
known co-receptors, only the TβR-III receptor
Fig. 4 BMP type I receptor discrimination by GDF-5. a The β1β2-loop of the BMP type I receptor BMPR-IA (Cα-trace in cyan) and BMPR-IB (gray)
adopt different conformations. Two alternative conformations are observed for this loop in the complex GDF-5:BMPR-IB; in contrast, the β1β2-loop of
BMPR-IA bound to GDF-5 R57A adopts a single locked conformation that is impossible if a large arginine side chain is at position 57 (as for example in
GDF-5WT). b As in (a) but rotated around the y-axis by 90 ° showing the putative steric clash between the side chains of His43 (cyan) in the β1β2-loop
of BMPR-IA and Arg57 of wild-type GDF-5 (green). c The β1β2-loop of BMPR-IA (cyan) bound to GDF-5 R57A and BMPR-IA (blue) bound to BMP-2 adopt
identical backbone and side-chain conformations
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(betaglycan) was differentially expressed, with levels 100
times higher in C2C12 cells. This co-receptor was recently
shown to act as a BMP cell surface receptor, and direct
and specific binding of this receptor to BMP-2, BMP-4,
and BMP-7 (and to a lesser amount to GDF-5) could be
demonstrated in cross-linking experiments [27]. To test a
possible modulation of GDF-5 signaling by this receptor
in ATDC-5 cells, we transfected these cells with a TβR-III
expression plasmid (kindly provided by P. ten Dijke,
Leiden) and analyzed GDF-5-mediated ALP induction.
However, a comparison of transfected and non-transfected
cells revealed no difference upon GDF-5 stimulation
(Additional file 5: Figure S4A). Similarly, transfection of
ActR-IIB into ATDC-5 cells did not alter GDF-5 respon-
siveness (Additional file 5: Figure S4B).
Ligand-induced ALP expression is mediated via the type I
receptor BMPR-IA
In our qPCR experiments, bmpr-1a transcripts showed
the highest abundance, whereas those of bmpr-1b were
found to have at least 10-fold lower expression in both cell
lines. However, because the number of receptors present
at the cell surface does not necessarily correlate with the
mRNA levels measured, we performed ALP assays with
ATDC-5 cells in which signaling through BMPR-IA was
blocked by a highly specific BMPR-IA-neutralizing Fab
antibody (AbD1564, AbD Serotec, Puchheim,
Germany). When applied with both factors used here,
the neutralizing antibody caused a dose-dependent re-
duction of ALP activity (Fig. 6a; Additional file 6: Fig-
ure S5). Most importantly, the signaling derived from
application of exogenous BMP-2 and GDF-5 was quanti-
tatively abolished upon application of high antibody con-
centrations because ALP activity was attenuated even
below background levels (i.e., levels without ligand
addition pointing to the presence of endogenous BMPR-
IA-binding TGF-β family ligands). The differences in the
antibody concentrations required for half-maximal inhib-
ition (IC50) of either BMP-2, GDF-5, or its variant R57A
directly correlate with their binding affinities for the re-
ceptor BMPR-IA [17]. The affinity of the neutralizing anti-
body for BMPR-IA (KD = 2.2 nM) is higher than that of
GDF-5 for BMPR-IA (KD = 20 nM) but slightly lower than
the receptor affinities of BMP-2 (KD = 0.8 nM) or GDF-5
Fig. 5 Ligand-mediated induction of alkaline phosphatase (ALP) expression. a Dose-dependent induction of ALP gene expression in C2C12 cells.
The background absorption signal of 0.08 ± 0.004 at 405 nm was subtracted from all data points. The ALP activity induced by 250 nM of BMP-2
was normalized to 100 %. b Inhibition of BMP-2-induced ALP expression by increasing concentrations of GDF-5 proteins. Half-maximal inhibitory
concentrations (IC50) of 70 nM and 5 nM were observed for wild-type GDF-5 (wt) and GDF-5 R57A, respectively. Expression levels (mRNA) of
receptors (c) and co-receptors (d) in C2C12 (blue bars) and ATDC-5 (purple bars) cells were determined by real-time reverse transcription polymerase
chain reaction. Bars represent mean values of two individual experiments. All values were normalized to HPRT gene expression. (For primer sequences
and statistics see Additional file 4: Table S1)
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R57A (KD = 1.6 nM). In summary, our data clearly identi-
fied BMPR-IA as the sole type I receptor mediating BMP-
2-induced as well as GDF-5-induced ALP activity in
ATDC-5 cells.
Antagonistic activities of GDF-5 are not related to signal
transduction via the SMAD pathway
Owing to the similar receptor and co-receptor expres-
sion pattern in ATDC-5 and C2C12 cells, we tried to
unravel why C2C12 cells do not express ALP in re-
sponse to GDF-5 and, furthermore, how GDF-5 can act
as a BMP-2 antagonist in this cell line. One possible
mechanism for a GDF-5-mediated antagonism might be
related to a sequential order of the receptor recruitment
and activation [13]. Because GDF-5, similar to BMP-2,
binds first to the type I receptor BMPR-IA, recruitment
of the type II to this intermediate GDF-5:BMPR-IA com-
plex and/or the subsequent activation of BMPR-IA
might then be impeded in C2C12 cells, explaining the
difference in signaling. We therefore tested whether
addition of wild-type GDF-5 or the BMP-2 mimic GDF-
5 R57A leads to the formation of signaling-competent
receptor complexes by analyzing the phosphorylation
status of SMAD molecules, given that this signaling cas-
cade directly depends on ternary ligand–receptor com-
plex formation (Fig. 6b).
In contrast to ALP expression, which in C2C12 cells
was only induced by BMP-2, SMAD-1 phosphorylation
was observed after exposure to BMP-2, GDF-5, and
GDF-5 R57A at similar levels in both ATDC5 and
C2C12 cell lines. The signals were stable over a period
of 72 h (Additional file 7: Figure S6), as published for
BMP-2 previously [17]. For wild-type GDF-5, about 10-
fold higher concentrations were required to achieve
phospho-SMAD levels comparable to those resulting
from BMP-2 stimulation, which again directly correlates
with the affinity differences for BMPR-IA binding of
GDF-5 and BMP-2. Because ternary ligand–receptor
complex formation is an essential prerequisite for SMAD
activation, but is observed here in ALP-positive ATDC-5
as well as in ALP-negative C2C12 cells, cell-specific differ-
ences in the recruitment of the type I and type II receptors
by GDF-5 as compared to BMP-2 seem highly unlikely.
Because the p38 MAP kinase pathway has been previously
described in the context of GDF-5 as well as in BMP-2
signaling [28–30], we then investigated p38 MAP kinase
levels and activation upon GDF-5, GDF-5 R57A, and
BMP-2 stimulation. ATDC-5 cells exhibited lower p38
MAP kinase expression compared to C2C12 cells, and
only the latter showed p38 MAP kinase activation upon
treatment with the different BMP proteins. However, no
significant differences could be observed between the indi-
vidual factors (Additional file 7: Figure S6). Thus, the data
presented here strongly point to additional component(s)
in either ATDC-5 or C2C12 cells, which either facilitate
ALP induction by GDF-5 in the former or suppress GDF-
5-mediated ALP induction in the latter cell line.
Agonist and antagonist activities of GDF-5 are also
observed in vivo
The C2C12 cell line was originally obtained from muscu-
lar tissue from mice [31] and its specific pre-myoblastic
properties, e.g., their potency to differentiate into multinu-
clear myotubes upon serum starvation, are maintained.
Addition of certain subset of BMPs leads to differentiation
towards the osteoblastic lineage. This cell line therefore
Fig. 6 Inhibition of ligand-induced signal transduction. a Dose-dependent inhibition of ALP gene expression induced by BMP-2 (black squares),
GDF-5 (red diamonds), or GDF-5 R57A (blue asterisks) by increasing concentrations of the BMPR-IA-neutralizing Fab antibody AbD1564. The background
absorption signal (without ligand, dotted line) of 0.36 ± 0.04 at 405 nm was not subtracted to highlight ALP induction mediated by endogenously
expressed BMP ligands. Half-maximal inhibitory antibody concentrations (IC50) for ALP activities induced by the different ligand proteins are indicated.
A biological duplicate of this experiment is shown in Additional file 6: Figure S5. b Ligand-induced SMAD-1 phosphorylation in C2C12 cells. The cells
were serum-starved and exposed to the indicated ligands for 1 h. Equal amounts of whole cell lysates were separated by SDS-PAGE and western blots
were performed using an anti-SMAD-1 or anti-pSMAD-1 antibody
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resembles somewhat the situation in muscular tissues of
animals in which ossicles form ectopically upon BMP-2
implantation. To compare the biological activities of the
ligands observed in our cell-based assays with data from
an in vivo model, carriers were doped with ligands and
implanted into the hind limbs of rats. Additionally, the lig-
and proteins were also implanted at an orthotopic site in
order to get information on their osteoconductive proper-
ties (Fig. 7).
Analyses of these experiments provided quantitative
data on the osteoconductive properties of all ligand
proteins tested in the orthotopic model (Fig. 8a, for sta-
tistics see Additional file 8: Table S2). Using 4 μg of
BMP-2 resulted in bone formation corresponding to
about 40 mm2 surface area and served as a reference for
the other ligands. Implanting 4 μg of GDF-5 R57A re-
sulted in a slightly smaller amount of bone formation. In
contrast, wild-type GDF-5 required about 20-fold more
protein than BMP-2 or GDF-5 R57A to obtain ossifica-
tion of the same surface area. These results fully corres-
pond with the ALP-inducing properties of these ligand
proteins in ATDC-5 cells [18, 19] and also correlate with
the in vitro affinities of these ligands for BMPR-IA.
Based on the attenuated osteoconductive potential of
wild-type GDF-5 in the calvaria, we assume that this
process—as for the induction of ALP expression in
ATDC-5 cells—involves the type I receptor BMPR-IA.
Upon implantation of the ligands at the heterotopic
site (here: muscle) we observed a very different picture
(Fig. 8b, for statistics see Additional file 9: Table S3).
The ability of BMP-2 to induce the formation of ectopic
bone at heterotopic sites has long been known [32],
whereas these properties are controversial in GDF-5.
Recently, Kakudo and colleagues reported that GDF-5
induced the formation of ectopic bone in rat leg mus-
cles, but they used an excessive dose of more than
300 μg of wild-type GDF-5 [33]. In comparison, different
reports have shown that 2 μg or less of recombinant
BMP-2 can induce ectopic bone growth [34–36]. In our
experiments, a direct comparison of the ligand proteins
after implantation at heterotopic sites showed that ec-
topic bone formation was indeed induced by BMP-2 as
well as by GDF-5 R57A. However, 10-times more of the
BMP-2 mimic GDF-5 R57A protein was required to in-
duce bone formation of a similar degree, despite its re-
ceptor binding properties being identical to those of
BMP-2. Wild-type GDF-5 did not induce any bone for-
mation even at very high doses (80 μg). Even more sur-
prising, application of a combination of BMP-2 with
increasing amounts of GDF-5 R57A first led to a clear
reduction in bone formation compared to application of
BMP-2 alone (see Fig. 8b columns 13 and 14, 4 μg
BMP-2 plus 4 μg GDF-5 R57A, and 4 μg BMP-2 plus
40 μg GDF-5 R57A). This observation strongly indicates
that BMP-2 and GDF-5 R57A utilize the same BMP re-
ceptors in this in vivo environment because the presence
of GDF-5 R57A led to direct attenuation of BMP-2 ac-
tivity. Consistently, wild-type GDF-5—showing no bone
formation up to amounts of 80 μg—could also efficiently
antagonize BMP-2 activity in a clear dose-dependent man-
ner. Because GDF-5 R57A binds BMPR-IA with about
10–20-fold higher affinity than wild-type GDF-5, the vari-
ant could also block BMP-2-induced bone formation
more efficiently (see Fig. 8b columns 13 and 19, 4 μg
BMP-2 plus 4 μg GDF-5 R57A, and 4 μg BMP-2 plus
80 μg GDF-5). These observations in vivo somewhat
Fig. 7 Ligand implantation assay in rat. Insoluble collagenous bone matrix cylinders doped with BMP-2, GDF-5, or GDF-5 R57A were implanted
into a hind-limb muscle (a) or the calvaria (b) of male adult Sprague Dawley rats with a body weight of 400 ± 50 g. The cylinders were explanted
28 days post implantation and radiographs of the specimen were taken. Bone regeneration was assessed by quantifying the area of newly formed
bone of the total explant (c) or in the defect site (d)
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resemble the BMP-2 antagonizing properties of GDF-5
and its variant found in the in vitro ALP-induction experi-
ments in C2C12 cells (see Fig. 5b).
However, when larger amounts of GDF-5 R57A were
applied together with BMP-2, the intrinsic activity of the
GDF-5 variant (Fig. 8b, column 6, 80 μg GDF-5 R57A)
then resulted in bone formation similar to that seen for
GDF-5 R57A alone, but no synergistic or additive effects
were observed when both osteoconductive factors were
simultaneously applied. This suggests that GDF-5 R57A,
although recruiting the same BMP type I and type II re-
ceptors as BMP-2 and doing so with the same affinities,
exhibits a dose-dependent activity distinct from BMP-2
in this cellular environment. Combining the observa-
tions from the in vivo and cell-based in vitro studies in-
dicates that, dependent on the cellular context and with
respect to certain cellular signals, GDF-5 can act either
as an agonist or antagonist of BMP-2, which might have
important implications in processes where both factors
act simultaneously on a heterogeneous population of
cells, as would be the case, for example, in the develop-
ing joint.
Discussion
An intriguing feature of the TGF-β superfamily is the
limited specificity of its ligand–receptor interactions
arising from the numeral discrepancy of sharing only
seven type I and five type II receptors among the more
than 30 ligands identified in mammals to date. A further
reduction in the signaling variety—disregarding cross
talks with other pathways—is due to the fact that this
large number of ligands principally activates only two
different SMAD signaling pathways. This strong signal
convergence raises important questions on how these
proteins can then encode so many different cellular (and
ligand-specific) functions.
Structural analyses of different ligands in complex with
the type I receptors BMPR-IA and BMPR-IB have
revealed differences in the orientation of the type I re-
ceptors in these complexes. A comparison of the com-
plexes BMP-2:BMPR-IAEC and GDF-5:BMPR-IBEC
showed an altered tilting between the two receptor moi-
eties in the complex by 20 ° (10 ° for each receptor ecto-
domain), with the membrane-distal part of BMPR-IBEC
moving into the wrist epitope and the membrane-
proximal part moving out of the wrist epitope of GDF-5
[24]. However, because complexes of two different li-
gands bound to different type I receptors were compared
here, the nature and significance of this change in lig-
and–receptor architecture remained unclear. With the
structure of GDF-5 R57A bound to BMPR-IAEC, we have
here been able to compare these differences, and found
that the change in tilting of the two type I receptor moi-
eties seems to be ligand-specific. The type I receptors
BMPR-IB and BMPR-IA share almost identical (within 1
°) tilt angles in the complexes GDF-5:BMPR-IBEC and
GDF-5 R57A:BMPR-IAEC, whereas both complexes show
a similar difference compared to the orientation of
BMPR-IAEC in the complex BMP-2:BMPR-IAEC. Al-
though this change in type I receptor orientation may
seem small, it might nevertheless contribute to a different
signaling output for both factors. Furthermore, the structure
of another BMP ligand–receptor complex, BMP-9 bound
to the type I receptor Alk1 and the type II receptor ActR-
IIB, has been determined [37], and shows an even stronger
tilting of the type I receptor extracellular domain Alk1 in
the complex, suggesting that the ligand–receptor architec-
ture differs for different BMP ligands. This architectural
variance might provide a possible mechanism for ligand-
specific signals even when using overlapping sets of recep-
tors if the orientation difference can be transmitted across
the membrane.
For receptors with a single transmembrane helix, re-
ceptor activation was originally assumed to occur via
ligand-induced receptor dimerization or oligomerization
as determined for the human growth hormone (hGH)
Fig. 8 Ligand-induced bone formation in vivo. Quantification of the ossified surface areas induced by the indicated amounts of ligands doped on
the implanted insoluble collagenous bone matrix cylinders. The data represent mean values of explants from at least five individual animals.
a Orthotopic model (calvaria); b heterotopic model (hind-limb muscle). For statistics, see Additional file 8: Table S2 and Additional file 9: Table S3
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[38]. This simplistic activation mechanism, relying purely
on dimerization/oligomerization of two receptor subunits,
thereby bringing intracellular domains into close proxim-
ity, has been challenged in the past 10 years by several
studies on typical receptor family members such as
the erythropoietin (EPO) and hGH receptors. The first
surprising data, from Livnah et al., showed that EPO mi-
metics (EMP) forming symmetrical EMP:(EPOR)2 ligand–
receptor complexes can activate the receptor, but that
mimetics forming an asymmetric EPO receptor complex,
deviating from a 180 ° symmetrical dimer by 15 °, re-
mained inactive [39]. Although this orientation-dependent
activation hypothesis for single transmembrane receptors
was initially debated because of the suggestion that other
properties of this EPO mimetic could result in loss of ac-
tivity [40], subsequent studies supported that activation of
single transmembrane receptors might be beyond a
ligand-induced encounter of the cytoplasmic domains.
That (proper) receptor–receptor orientation plays an im-
portant role in downstream signaling transduction was
confirmed by three elegant experiments. One used a set of
monoclonal antibodies that could arrange two receptors
in different dimer assemblies [41]; another used coiled-
coil domains as ligand replacements and altered their
dimer architecture [42]; and a third introduced or deleted
residues within the transmembrane helix to alter the hel-
ical pitch and relative orientation of the two receptor sub-
units in the dimer arrangement [43].
The above-depicted mechanism provides a potential
scenario for how two different ligands such as GDF-5
and BMP-2 might generally encode different signals via
an identical receptor assembly, and is helpful in explain-
ing the functional diversity of BMP ligands on the whole.
However, it cannot explain the difference in the signaling
characteristics of GDF-5 (or its variant R57A) observed
here between the two cell lines C2C12 and ATDC5 or
between the heterotopic and orthotopic ossification
model, because we have to assume that the ligand-specific
differences in the receptor architecture are identical in
both cell lines and in both tissue environments.
Another explanation of why the ossification potency of
GDF-5 and BMP-2 differed in the in vivo experiments
might be the different release of both growth factors
from the carrier (resulting from different diffusion/solu-
bility properties). However, one would then expect simi-
lar results in both ossification models, because the
carriers used in both models were identical. Further-
more, diffusive properties of the mature form of BMPs
seem to be regulated by ECM binding sites usually formed
by a stretch of positively charged residues present in the
N-terminus of these factors [44]. The N-terminal regions
of GDF-5 and BMP-2 are, however, similar in length and
contain a comparable number of basic residues, likely in-
dicating similar ECM binding properties.
What potential mechanisms could then lead to cell
type-specific and ligand-specific signaling differences for
GDF-5 and enable GDF-5 to act as a context-dependent
antagonist against BMP-2? Possibly the simplest explan-
ation without considering thus far unknown components
would be the formation of heteromeric receptor assem-
blies in a cell type-dependent manner. But GDF-5 and
BMP-2 exhibit no ligand-specific affinity differences for
their three type II receptors [17]: a heteromeric receptor
assembly with a ligand-specific type II receptor stoichi-
ometry therefore seems unlikely. In addition, the mRNA
levels for ActR-II and BMPR-II do not differ between
ATDC5 and C2C12 cells, and ActR-IIB seems absent in
both cell lines (see Fig. 5c). The only other type I recep-
tors except for BMPR-IA and BMPR-IB that activate
SMAD1/5/8 (and therefore could potentially be acti-
vated via GDF-5 and BMP-2) are ActR-IC (also known
as TSR-I), which within the BMP/GDF subgroup is
highly specific for BMP-9 and BMP-10 [37], and ActR-I
(also known as Alk2). Although the BMP type I receptor
Alk2 was shown to be involved in endochondral ossifica-
tion via regulation of the proliferation and differentiation
of chondrocytes [45], Alk2 seems an unlikely candidate
to explain the differences in GDF-5 signaling. Alk2 was
shown to require N-glycosylation at a conserved site in
the ligand for binding and activation [46], which is lack-
ing in GDF-5. Thus, irrespective of the fact that the
mRNA levels for ActR-I were highly similar in ATDC5
and C2C12 cells, a cell type-dependent differential par-
ticipation of Alk2 in a GDF-5-based heteromeric recep-
tor complex seems unlikely.
Other components that potentially modulate signal
transduction of TGF-β members derive from the large
group of modulator proteins, e.g., noggin, follistatin, and
members of the chordin and DAN family. These se-
creted proteins are present in the extracellular space and
alter the activities of the ligands by binding to and block-
ing their interaction with their cellular receptors, thereby
essentially decreasing the concentration of the “free” lig-
and. The interactions of these modulators can exhibit re-
markable ligand specificity even for closely related
ligands such as BMP-6 and BMP-7 [47]. Owing to the
modulator’s own ligand-specificity profile, these proteins
might thus individually fine-tune the active concentra-
tion for each TGF-β ligand present at the site of action,
thereby establishing a defined equilibrium for a set of
ligands that together yield an accurately defined bio-
logical response in the target cells. Whereas such a
simple ligand-dependent modulatory mechanism would
be consistent with the higher concentrations required
for GDF-5 to initiate induction of ALP expression in
C2C12 cells, it does not fit our observation that GDF-5
can effectively antagonize BMP-2 in these cells. The
latter requires that GDF-5 binds to the same receptor
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assembly through which BMP-2 is signaling without
activating this receptor, and thus a decrease in the con-
centration of free GDF-5 through the actions of a
modulator protein is in contrast with its antagonistic
property.
This strongly points towards an additional membrane-
located component(s), whose presence differs in the
different cellular environments and which participates
either in the ligand-receptor complex of GDF-5 or of
BMP-2, and thereby influences the signaling output of
that factor. For instance, the presence of such an add-
itional component in ATDC5 cells (or in the calvaria)
could render GDF-5 signaling active in this context. But
in C2C12 cells (or at heterotopic sites), where this com-
ponent is missing, GDF-5 would still assemble a recep-
tor complex composed of the same BMP receptors and
thus be able to antagonize BMP-2 activity, but unable to
induce—at least parts of—the downstream signaling cas-
cade. One group of molecules that fulfills these criteria
comprises the various BMP/TGF-β pseudo-receptors
and co-receptors. Some of these co-receptors adjust the
signaling potential of particular ligands via the relatively
simple mechanism of enhancing the ligand’s binding af-
finities to the sites of action. For instance, glypicans,
which are multifunctional glycosylphosphatidylinisotol
(GPI)-anchored heparin sulfate proteoglycans, were found
to modulate the signaling cascades of regulatory proteins
such as Wnt, Sonic Hedgehog, TGF-β members, and
Fibroblast Growth Factors (FGFs) [48]. Six glypican mem-
bers are found in humans and mice and, for the glypican
LON-2 of Caenorhabditis elegans as well as the glypican
Dally of Drosophila, direct binding to BMP members has
been shown [49, 50]. Glypican 3 and BMP-4 likely cooper-
ate during limb and skeletal development given that het-
erozygous mutations in bmp-4 in combination with
hemizygous mutations in gpc-3 dramatically enhance the
polydactyly phenotype seen in bmp-4 heterozygous mice
[51]. Another BMP-specific group of co-receptors is the
so-called repulsive guidance molecules (RGMs) co-
receptor family, i.e., DRAGON/RGMb, RGMa, and
Hemojuvelin/RGMc, which initially were thought to act
via an affinity-enhancing mechanism [52]. Owing to their
nature as GPI-anchored proteins without an intracellular
domain, a direct influence on signaling other than enhan-
cing the local concentration of the ligand seems
impossible. However, RGMa was shown to alter type II re-
ceptor specificity, possibly leading to a qualitatively differ-
ent signaling output when RGMa is present [53]. Recent
structural/functional analyses of the RGM–BMP inter-
action have revealed an even more complex picture [54].
Because the binding site of RGM co-receptors on BMPs
highly overlaps that for BMP type I receptors, a strong at-
tenuation of BMP signaling would be expected in the
presence of RGM co-receptors, the opposite of what is
observed [52, 55, 56]. Siebold and colleagues suggested
that upon internalization of BMP–RGM-type II receptor
complexes by endocytosis, these complexes might be tar-
geted to endosomal compartments. Here, BMP dissociates
from the RGM co-receptor owing to the pH-dependent
nature of this interaction and forms a ternary complex
with a BMP type I and type II receptor, the former of
which can undergo constitutive endocytosis [54]. Signaling
from this compartment might then have a different out-
put, allowing for ligand-specific and context-specific sig-
naling ([54], see also [57]). Could one of the members of
the RGM family therefore represent the sought-after
GDF-5 co-receptor? Again, because the expression levels
for all three RGM members seem similar in GDF-5-
responsive (ATDC5) as well as non-responsive cells
(C2C12), it seems very unlikely that their presence or ab-
sence alters the cell responsiveness to GDF-5.
The most pronounced effect on ligand-mediated sig-
naling is linked to the presence of the co-receptors
betaglycan (TβR-III) or cripto. Betaglycan can act as a
co-receptor in TGF-β signaling [58], but is also required
for inhibin function [59]. In the presence of betaglycan, in-
hibin binds the type II receptors ActR-II, ActR-IIB, and
BMPR-II, thereby inhibiting not only activin, but also sig-
naling of certain BMPs (i.e., BMP-2, BMP-7, and GDF-5)
[60]. A similar modulating function was described for the
GPI-anchored membrane protein cripto, which is required
for receptor assembly and activation of members of the
nodal family [61] and GDF-1/Vg1[62]. Cripto binds nodal
independently of TGF-β receptors via its EGF-like domain
and ActR-IB via its CFC domain [63, 64], thus facilitating
signaling of this ligand. Cripto also binds to activin but
only in the presence of ActR-II/IIB. At the same time,
cripto binding to activin blocks the interaction with ActR-
IB and subsequently prevents the ligand-mediated associ-
ation of ActR-IB with ActRII/IIB [65]. Thus, cripto
controls the differential use of (or access to) the activin re-
ceptor by different ligands. These regulatory properties of
betaglycan and cripto are reminiscent of our observations
obtained from in vitro as well as in vivo experiments in
that a not-yet identified co-receptor possibly triggers the
biological activity of GDF-5. Theoretically, two opposing
mechanisms are feasible: The first mechanism involves an
antagonizing GDF-5 specific co-receptor, whose presence
still allows binding of GDF-5 to its cognate receptors, but
prevents subsequent processes required for certain bio-
logical responses such as the induction of ALP gene ex-
pression. This hypothetical inhibiting co-receptor would
be present in vivo in muscular tissue or—in our cell line
model—in C2C12 cells. Given that BMP-2 and GDF-5
utilize the same subset of BMP type I and type II recep-
tors, this hypothetical inhibitor would enable the antagon-
istic properties of GDF-5. The second mechanism
postulates an activating co-receptor specifically required
Klammert et al. BMC Biology  (2015) 13:77 Page 13 of 18
for GDF-5 to signal. In this case, the co-receptor must be
present in tissue or cells in which osteogenic markers—
like in the calvarial model or in ATDC-5 cells—are indu-
cible upon GDF-5 addition. The latter mechanism seems
more likely, because addition of GDF-5 led to SMAD
activation in ALP-positive ATDC-5 as well as in ALP-
negative C2C12 cells, showing that a defined subset
of signals can still be transduced in the absence of
the GDF-5-specific activating co-receptor.
Conclusions
Besides the aspect that GDF-5 cannot induce the full sig-
naling cascade in all cell lines and tissues but possibly re-
quires additional components for this functionality, our
study also revealed a remarkable BMP-2 antagonizing
function for GDF-5, which is dependent on the cellular
context. This is of particular interest because GDF-5 can
possibly inhibit the process of ossification mediated by
BMP-2 and BMP-4. GDF-6 might share the same func-
tion, because Shen et al. showed a GDF-6-dependent in-
hibition of osteogenic differentiation of mesenchymal
stem cell [66]. The BMP-2 antagonistic function of GDF-5
and possibly also of GDF-6 might shed new light onto the
joint forming process. Possibly GDF-5 and GDF-6 are only
required for a fine-tuning of pro-chondrogenic/osteogenic
and anti-chondrogenic/osteogenic stimuli caused by other
BMPs or modulator proteins such as noggin. Such a sce-
nario would explain the relatively mild phenotypes of gdf-
5 null mice as well as those caused by different activating
or deactivating gdf-5 mutations in human. A fascinating
aspect in this context is that malformations of particular
joints are coherently linked to certain mutations in GDF-5.
It can therefore be assumed that every joint requires an in-
dividually fine-balanced equilibrium of pro-chondrogenic
and anti-chondrogenic factors.
Methods
Expression and purification of recombinant proteins
Expression and purification of Escherichia coli-derived
recombinant human BMP-2, human GDF-5, and the
mutant GDF-5 R57A was carried out as previously de-
scribed [19, 26, 67]. The extracellular domain of mature
human BMPR-IA [Swiss-Prot:P36894] comprising resi-
dues 24–152 was expressed in E. coli as thioredoxin-
fusion protein using a protocol similar to those previously
described [25, 26, 68]. Purity and homogeneity of the re-
combinant proteins were validated by sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS-PAGE),
analytical reverse-phase high-performance liquid chro-
matography and electrospray ionization Fourier trans-
form ion cyclotron resonance mass spectrometry. For
additional quality control, the affinities for binding of
the BMP-2 and GDF-5 proteins to BMPR-IA and other
type I and type II receptors were determined by surface
plasmon resonance as previously described and com-
pared to published data [17].
Crystallization of the binary complex GDF-5 R57A:BMPR-IA
The binary complex of the GDF-5 variant R57A bound
to the extracellular domain of BMPR-IA was obtained
and purified similar to the complex GDF-5:BMPR-IBEC
[68]. Full details of the preparation of the complex and
the crystallization have been published elsewhere [67].
Crystals of different morphology were grown from vapor
diffusion setups using magnesium formate, ammonium
citrate, or polyethylenglycols of various length as precipi-
tants and with pH ranging from 5.5 to 8.0. Crystallization
conditions were optimized by varying temperature, buffer
chemistry, and pH, as well as the concentration of the
precipitants. Only crystals exhibiting a hexahedral or
rhombohedral form diffracted X-rays to high resolution
and were thus suitable for data acquisition. Those crystals
with final dimensions of 300 × 200 × 80 μm were obtained
within 4 weeks from 0.1 M HEPES pH 7.5, 0.2 M NaCl,
and 20 % PEG 3350 at room temperature.
Data acquisition, processing, and structure analysis
The high-resolution native data were collected from a
single crystal at 100 K using a home source (Micro-
Max007 Xray generator, VariMax HighRes optics and a
R-AXIS IV++ image plate system, Rigaku, The Wood-
lands, Texas, USA). Diffraction data with a maximal
resolution of 2.28 Å were obtained from a 123 ° sweep
using 0.5 ° oscillation and 360 s exposure time per
frame. The data were indexed and scaled using the soft-
ware CrystalClear 1.3.6 (Rigaku). The crystal of the GDF-5
R57A:BMPR-IAEC complex belongs to the spacegroup I2
with unit cell constants of a = 63.81 Å, b = 62.85 Å, c =
124.99 Å, and β = 95.85 °. Initial phasing was performed
by molecular replacement using the software package
CNS 1.2 and the structure of the binary complex of BMP-
2 bound to BMPR-IA [PDB:1REW] as a search template;
full technical details of the initial phasing analysis have
been published elsewhere [67]. The amino acid sequence
of the BMP-2 template was adapted by manual rebuilding
to cover the sequence of GDF-5 R57A using the software
Quanta2008 (MSI Accelrys, San Diego, CA, USA). The
structure of the binary complex GDF-5 R57A:BMPR-IA
was then refined by iterative cycles of manual rebuilding
using Quanta2008 and refinement using Refmac version
5.02 of the software package CCP4. During refinement,
one TLS group was defined per molecule chain (one TLS
group per GDF-5 monomer and one TLS group for each
BMPR-IAEC molecule) to account for anisotropy in the
data. The progress of refinement was monitored by cross-
validation using a test data set comprising 5 % of the re-
flections. In the final refinement cycles Fobs-Fcalc difference
electron density maps were used to identify water
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molecules located within 5 Å of the protein complex. The
final structure of the GDF-5 R57A:BMPR-IAEC complex
comprised 3,015 protein atoms and 93 water molecules.
The R-factor was 0.19 for Rcryst and 0.24 for Rfree. Statistics
for data processing, refinement, and structure quality are
given in Table 2. The structure has been deposited at the
RCSB databank [PDB:3QB4] [69].
Alkaline phosphatase assay
The teratocarcinoma AT508-derived cell line ATDC-5
(RIKEN, No. RCB0565) was cultured in a 1:1 ratio of
Dulbecco’s modified eagle medium (DMEM) and Ham’s
F12 medium containing 5 % (v/v) fetal calf serum (FCS),
and antibiotics (100 units ml−1 of penicillin G and
100 μg ml−1 of streptomycin). Promyoblastic C2C12
cells (ATCC CRL-172) were grown in DMEM containing
10 % (v/v) FCS and the same antibiotics. For ALP assays,
the cells were serum-starved (2 % FCS) and exposed to
ligands or to mixtures of ligands and neutralizing anti-
bodies for 72 h in 96-well microplates. After cell lysis,
ALP activity was measured by p-nitrophenylphosphate
conversion using an enzyme-linked immunosorbent
assay reader at 405 nm. All experiments were performed
two times in duplicate. ALP assays using the neutralizing
BMPR-IA antibody were performed in two independent
experiments. For data presentation of raw data (non-
normalized), a single experiment is shown in Fig. 6a, the
duplicate is shown in Additional file 6: Figure S5.
Quantification of BMP-receptors and co-receptors by
qRT-PCR
RNA of C2C12 or ADTC-5 cells was extracted using the
RNeasy Plus Mini Kit (Qiagen, Hilden, Germany) ac-
cording to the supplier’s instructions. Purified RNA was
reversely transcribed by murine Moloney leukemia virus
reverse transcriptase using random hexamer oligonucle-
otides. cDNA was subjected to qRT-PCR. The experi-
ments were performed in duplicate. The data were
normalized to HPRT expression (for primer sequences
and statistics, see Additional file 4: Table S1).
Western blot analysis
To determine of SMAD or p38 MAP kinase activity cells
were simulated with either 10 nM of BMP-2, 10 nM of
GDF-5 R57A or 100 nM of GDF-5 for the indicated time
points. Cells were lysed and cellular debris was subse-
quently removed by centrifugation. Protein-containing
supernatants were separated by SDS-PAGE and blotted
onto nitro-cellulose membranes. The membranes were
blocked and incubated with the indicated anti-
bodies (anti-SMAD-1, -p-SMAD-1, -p38 MAPK, and -P-
p38 MAPK; Cell Signaling Technology, Danvers, MA,
USA). For detection, secondary antibodies coupled to
horseradish peroxidase were used (anti-mouse IgG, anti-
rabbit IgG; Cell Signaling Technology, Danvers, MA,
USA). Chemoluminescence was analyzed using a Fluor
Chem Q gel documentation system (Cell Biosciences,
Victoria, Australia).
Preparation of carrier derived from equine bone
Equine bone was freshly harvested and cleaned from the
surrounding soft tissues. Blocks of cancellous bone were
cut and stored at −80 °C until further processing. After
thawing, the bone marrow and fat was removed by cen-
trifugation at 1000 × g. The cancellous blocks were then




Unit cell a = 63.81 Å, b = 62.85 Å,
c = 124.99 Å α = γ = 90 °,
β = 95.85 °
Wavelength (Å) 1.5418
Resolution (Å) 24.0–2.28 (2.40–2.28)
No. reflections 51,824 (7,550)
No. unique reflections 22,044 (3,177)
Rmerge 0.066 (0.384)
<(I)/σ (I)> 7.4 (2.0)
Completeness (%) 97.8 (97.4)
Redundancy 2.4 (2.4)
Refinement
Resolution (Å) 23.8–2.28 (2.34–2.28)
Rwork/Rfree (%) 19.7 (25.8)/24.1 (34.4)
Correlation coefficient (Fobs-Fcalc)free 0.938





Bond length (Å) 0.013
Bond angles (°) 1.457
Torsion angles (°)b 8.345
Torsion angles (°)c 19.839
TLS 4 groups GDF-5 R57A
(chain A + C, residues 11–115,
10–115) BMPR-IA (chain B + D,
residues 31–118, 31–119)
Ramachandran analysisd
Number of residues in favored region 363 (95.5 %)
Number of residues in allowed region 16 (4.2 %)
Number of residues in outlier region 1 (0.3 %)
Values in parentheses are for the highest-resolution shell
aOne crystal was used to collect the diffraction data
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cleaned with pressurized steam. After defatting in metha-
nol and chloroform (1:1) the bone was washed in distilled
water and cut under constant irrigation into slices of 10 or
1 mm thickness. The slices were then demineralized in
0.5 M HCl. Completion of demineralization was assessed
by radiographic analysis. For calvarial reconstruction, discs
of 8 mm in diameter and 1 mm height were punched out
of the thin soft bone matrix. For heterotopic implantation,
cylinders of 5 mm in diameter and 10 mm thickness were
cut out of the thick matrix sheets. All carriers were steril-
ized in a methanol and chloroform mix (1:1) and washed
in sterile deionized water. For storage, implants were ly-
ophilized and kept at room temperature.
For doping with growth factors (4, 20, or 80 µg; 4 µg
of BMP-2 serve as reference), the lyophilized matrix was
hydrated in sterile deionized water. Growth factors were
then applied in 40 μl of aqueous solution evenly spread
on the porous carrier. Finally, the doped carriers were ly-
ophilized and stored at 4 °C in an air-sealed sterile
container.
Surgery
Male adult Sprague Dawley rats with a body weight of
400 ± 50 g (Charles River Breeding Laboratories, Sulzfeld,
Germany) were used for all studies. They were caged in
groups of four and fed ad libitum with a standard labora-
tory pelleted diet and water. Animals and wound condi-
tions were monitored daily. For surgery, a mixture of
ketamine hydrochloride (Ketavet (Parke-Davis, Berlin,
Germany); 120 mg/kg weight) and Xylazine (Rom-
pun (Bayer, Wuppertal, Germany); 5 mg/kg weight) was
intraperitoneally administered for anesthesia. Circulatory
parameters were monitored using a pulse oximeter at-
tached to the tail root. Heterotopic implantation was per-
formed by shaving the hind legs and subsequent
disinfection with 70 % ethanol. Following a small skin in-
cision a muscular pouch was formed by blunt preparation.
The cylindrical implants were inserted and positioned par-
allel to the diaphysis of the femur. The pouch as well as
the skin was closed with a resorbing suture.
Orthotopic implantation in calvarial defects was per-
formed after disinfection, transverse skin incision, and
resection of the periosteum in the area of craniotomy.
The craniotomy defect of 8 mm in diameter was pre-
pared with a trephine in a slow-speed dental hand piece
under constant irrigation with sterile 0.9 % physiologic
saline. The calvarial disk was dissected free, avoiding
dural perforations and keeping the sagittal venous sinus
intact. The lyophilized implant was directly placed in the
defect and held in place until it was fully soaked with
blood. The swelling following the rehydration of the
matrix ensured a tight and secure fit of the implanted
discs. The skin was closed with a resorbing suture.
Quantitative radiograph analysis
The animals were killed 28 days after implantation and
the specimens were retrieved, including the soft tissue
surrounding the calvaria bone. Radiographs of the speci-
men were taken using a FAXITRON X-Ray unit model
44385 (Hewlett Packard, McMinnville, OR, USA). Het-
erotopic implants were radiographed with 22 kV for
27 s. The explanted calvaria were placed with the exter-
nal cortical layer facing the film (Kodak Industrex SR)
and exposed with 20 kV for 30 s. The radiographs were
scanned with a Nikon Coolscan LS 2000 slide scanner at
600 dpi as 256-bit gray-scale images. Image analysis was
performed using the program NIH Image 1.61 (devel-
oped at the US National Institutes of Health and avail-
able on the Internet at [70]) in a Windows version
(Scion Corporation). Bone regeneration was assessed by
measuring the area of newly formed bone in the defect
site. Briefly, the median- and mean cortical densities and
their standard deviations (Mcd, SDcd) were determined
over a wide range of non-operated calvarial bone. The
thresholds of gray levels were set to Mcd ± 2*SDcd to mark
the total bone. The sites that were initially defective were
outlined manually and the area of newly formed bone was
measured from the latter images. For statistics see
Additional file 8: Tables S2 and Additional file 9: Table S3.
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Availability of supporting data
The structure has been deposited at RCSB databank
[PDB:3QB4].
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